The association of subjective sleep characteristics and plasma biomarkers of Alzheimer’s disease pathology in older cognitively unimpaired adults with higher amyloid-β burden

被引:0
作者
Heling Chu
Chuyi Huang
Ya Miao
Chenxi Ren
Yihui Guan
Fang Xie
Zhuo Fang
Qihao Guo
机构
[1] Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Department of Gerontology
[2] Renji Hospital,Health Management Center, School of Medicine
[3] Shanghai Jiao Tong University,PET Center
[4] Huashan Hospital,Department of Data and Analytics
[5] Fudan University,undefined
[6] WuXi Diagnostics,undefined
来源
Journal of Neurology | 2023年 / 270卷
关键词
Alzheimer’s disease; Sleep; Plasma biomarkers; Older cognitively unimpaired adults; F-florbetapir PET;
D O I
暂无
中图分类号
学科分类号
摘要
We aimed to investigate the association of subjective sleep characteristics and plasma Alzheimer’s disease (AD) biomarkers in older cognitively unimpaired adults with higher amyloid-β (Aβ) burden. Unimpaired cognition was determined by education-adjusted performance for the Mini-Mental State Examination and exclusion of dementia and mild cognitive impairment via standardized neuropsychological tests. We used Pittsburgh Sleep Quality Index (PSQI) to assess subjective sleep quality. The participants also underwent examination of plasma AD biomarkers and 18F-florbetapir PET scan. Correlation and multiple linear regression analyses were used to investigate the association between subjective sleep characteristics and AD biomarkers. A total of 335 participants were included and 114 were Aβ-PET positive. Multivariable regression analysis showed sleep duration > 8 h and sleep disturbance were associated with Aβ deposition in total participants. Two multiple linear regression models were applied and the results revealed in participants with Aβ-PET (+), falling asleep at ≥ 22:00 to ≤ 23:00 was associated with higher levels of Aβ42 and Aβ42/40. Other associations with higher Aβ42/40 and standard uptake value ratio contained sleep efficiency value, sleep efficiency ≥ 75%, no/mild daytime dysfunction and PSQI score ≤ 5. Higher p-Tau-181 level was associated with sleep latency > 30 min in Aβ-PET (+) group and moderate/severe sleep disturbance in Aβ-PET (–) group. Our data suggests sleep duration ≤ 8 h and no/mild sleep disturbance may be related to less Aβ burden. In participants with Aβ deposition, falling asleep at 22:00 to 23:00, higher sleep efficiency (at least ≥ 75%), no/mild daytime dysfunction, sleep latency ≤ 30 min, and good sleep quality may help improve AD pathology.
引用
收藏
页码:3008 / 3021
页数:13
相关论文
共 169 条
[1]  
Scheltens P(2021)Alzheimer's disease Lancet 397 1577-1590
[2]  
De Strooper B(2018)Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease Nat Rev Neurol 14 653-666
[3]  
Kivipelto M(2021)Association of β-amyloid level, clinical progression, and longitudinal cognitive change in normal older individuals Neurology 96 e662-e670
[4]  
Kivipelto M(2022)Differential effects of APOE and modifiable risk factors on hippocampal volume loss and memory decline in Aβ- and Aβ+ older adults Neurology 98 e1704-e1715
[5]  
Mangialasche F(2015)Meta-analysis of modifiable risk factors for Alzheimer's disease J Neurol Neurosurg Psychiatry 86 1299-1306
[6]  
Ngandu T(2020)Sleep problems and risk of all-cause cognitive decline or dementia: an updated systematic review and meta-analysis J Neurol Neurosurg Psychiatry 91 236-244
[7]  
van der Kall LM(2021)Association of short and long sleep duration with amyloid-β burden and cognition in aging JAMA Neurol 78 1187-1196
[8]  
Truong T(2020)Sleep characteristics and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact older adults: The CABLE study Alzheimers Dement 16 1146-1152
[9]  
Burnham SC(2019)Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease JAMA Neurol 76 791-799
[10]  
Rosenich E(2021)A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis Mol Neurodegener 16 30-339